PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15213263-4	2004	When hydralazine was administered to the mutant mice fed a high-salt diet, BP was reduced to 72.5 +/- 1.3 mmHg, with decreases in the levels of renal eNOS mRNA and protein expression to about half of those found in nontreated group.	Hydralazine	5-16	nitric oxide synthase 3, endothelial cell	Mus musculus	150-154	
11705813-3	2001	METHODS AND RESULTS: Male apoE/eNOS DKO mice were treated with hydralazine in their drinking water (250 mg/L) using a dose that lowers the blood pressure to levels seen in apoE KO mice.	Hydralazine	63-74	nitric oxide synthase 3, endothelial cell	Mus musculus	31-35	
11705813-5	2001	Hydralazine-treated, normotensive male apoE/eNOS DKO mice developed increased aortic lesion areas (30.0+/-2.8%, n=11) compared with male apoE KO mice (14.6+/-0.8%, n=7).	Hydralazine	0-11	nitric oxide synthase 3, endothelial cell	Mus musculus	44-48	
11705813-7	2001	Four of 11 hydralazine-treated male apoE/eNOS DKO mice developed abdominal aortic aneurysms.	Hydralazine	11-22	nitric oxide synthase 3, endothelial cell	Mus musculus	41-45	
14644766-8	2004	Long-term administration of hydralazine normalized the blood pressure and prevented the LV dilation in NOS3(-/-) mice but did not prevent the LV hypertrophy, dysfunction, and fibrosis associated with NOS3 deficiency after TAC.	Hydralazine	28-39	nitric oxide synthase 3, endothelial cell	Mus musculus	103-107